Skip to main content

Table 1 Epidemiological and baseline characteristics of the sample

From: The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement

 

total sample (N = 2026)

CS group (N = 131)

WW group (N=1895)

p-value

(mean ± SD)

(mean ± SD)

(mean ± SD)

Age

54.37 ± 14.67

63.44 ± 11.42

53.74 ± 14.66

<0.0001a

BMI

29.52 ± 5.87

29.82 ± 5.37

29.49 ± 5.90

0.5407a

ComS b

1.06 ± 1.15

1.63 ± 1.25

1.02 ± 1.13

0.0004c

PRS d

1.01 ± 1.55

3.75 ± 1.43

0.82 ± 1.37

<0.0001c

VC [%predicted]

100.52 ± 16.30

86.93 ± 17.25

101.48 ± 15.80

<0.0001c

FEV1/VC [%]

79.61 ± 6.80

79.96 ± 7.75

79.58 ± 6.73

0.2795c

TLC [%predicted]

105.37 ± 15.70

90.78 ± 16.36

106.40 ± 15.14

<0.0001c

RV [%predicted]

126.04 ± 30.42

108.24 ± 28.88

127.29 ± 30.14

<0.0001c

DLCOc [%predicted]

79.62 ± 16.53

57.69 ± 15.94

81.13 ± 15.46

<0.0001c

KCOc [%predicted]

89.00 ± 14.78

79.31 ± 16.00

89.67 ± 14.46

<0.0001c

 

n (%)

n (%)

n (%)

p -value e

Male sex

919 (45.36%)

85 (64.89%)

834 (44.01%)

<0.0001

Acute COVID-19 severity f

mild

1046 (51.63%)

7 (5.34%)

1039 (54.83%)

<0.0001

moderate

433 (21.37%)

27 (20.61%)

406 (21.42%)

0.9812

severe

513 (25.32%)

93 (70.99%)

420 (22.16%)

<0.0001

Persistent respiratory symptoms

dyspnea

1056 (52.12%)

105 (80.15%)

951 (50.18%)

<0.0001

cough

616 (30.40%)

48 (36.64%)

568 (29.97%)

0.1384

  1. aStudent’s t-test for two samples; bComorbidity score: calculated by adding 1 point for each of the following selected comorbidities: arterial hypertension, diabetes mellitus, ischemic heart disease, pulmonary embolism, dyslipidemia, hypothyroidism, bronchial asthma, chronic obstructive pulmonary disease, sarcoidosis, interstitial lung disease. The score was available in 652 subjects (46 in the CS group and 606 in the WW group); cMann-Whitney U test; eChi-square test; fmild: no pneumonia, no oxygen therapy, moderate: pneumonia not requiring oxygen therapy, severe: pneumonia requiring oxygen therapy